首页 > 最新文献

Acta Clinica Belgica最新文献

英文 中文
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients. 索拉非尼治疗头颈部腺样囊性癌的疗效和毒性:5例患者的病例系列。
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-10-01 Epub Date: 2019-06-23 DOI: 10.1080/17843286.2019.1633490
Karen Couvreur, Jacobs Celine, Bock Marlies, D'Hondt Randal, Deron Philippe, Duprez Frederic, Rottey Sylvie

Introduction: Adenoid cystic carcinoma (ACC) of the head and neck is a rare malignancy of the salivary glands that accounts for approximately 10% of salivary gland carcinoma. Despite aggressive local therapy, local recurrence and distant metastases occur frequently. Response rates (RR) to potential curative and palliative chemotherapy are limited, so new strategies are needed.

Case reports: We describe five case reports of patients with unresectable locally advanced or metastatic ACC of the head and neck who have been treated with sorafenib, a multi-tyrosine kinase inhibitor (mTKI).

Results: In this case series, we found that three out of five patients treated with sorafenib survived, respectively, 16, 35 and 35 months. Two patients showed a partial response (PR) and one patient had a prolonged stable disease (SD) for almost three years. Grade 3 adverse events (AE) occur under sorafenib so adequate toxicity management is essential. This retrospective case series hints towards the possibility of clinical benefit for treating ACC patients with sorafenib. Efficacy of sorafenib should be studied in a prospective-randomized clinical trial which is a challenging task due to the rarity of the disease.

头颈部腺样囊性癌(ACC)是一种罕见的唾液腺恶性肿瘤,约占唾液腺癌的10%。尽管积极的局部治疗,局部复发和远处转移是经常发生的。对潜在的治愈性和姑息性化疗的反应率(RR)有限,因此需要新的策略。病例报告:我们描述了5例不可切除的局部晚期或转移性头颈部ACC患者,他们接受了索拉非尼(一种多酪氨酸激酶抑制剂(mTKI))的治疗。结果:在这个病例系列中,我们发现5名接受索拉非尼治疗的患者中有3名分别存活了16个月、35个月和35个月。2例患者表现出部分缓解(PR), 1例患者的病情延长稳定(SD)近3年。3级不良事件(AE)发生在索拉非尼,因此充分的毒性管理是必不可少的。本回顾性病例系列提示索拉非尼治疗ACC患者的临床获益可能性。索拉非尼的疗效应该在前瞻性随机临床试验中进行研究,由于这种疾病的罕见性,这是一项具有挑战性的任务。
{"title":"Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.","authors":"Karen Couvreur,&nbsp;Jacobs Celine,&nbsp;Bock Marlies,&nbsp;D'Hondt Randal,&nbsp;Deron Philippe,&nbsp;Duprez Frederic,&nbsp;Rottey Sylvie","doi":"10.1080/17843286.2019.1633490","DOIUrl":"https://doi.org/10.1080/17843286.2019.1633490","url":null,"abstract":"<p><strong>Introduction: </strong>Adenoid cystic carcinoma (ACC) of the head and neck is a rare malignancy of the salivary glands that accounts for approximately 10% of salivary gland carcinoma. Despite aggressive local therapy, local recurrence and distant metastases occur frequently. Response rates (RR) to potential curative and palliative chemotherapy are limited, so new strategies are needed.</p><p><strong>Case reports: </strong>We describe five case reports of patients with unresectable locally advanced or metastatic ACC of the head and neck who have been treated with sorafenib, a multi-tyrosine kinase inhibitor (mTKI).</p><p><strong>Results: </strong>In this case series, we found that three out of five patients treated with sorafenib survived, respectively, 16, 35 and 35 months. Two patients showed a partial response (PR) and one patient had a prolonged stable disease (SD) for almost three years. Grade 3 adverse events (AE) occur under sorafenib so adequate toxicity management is essential. This retrospective case series hints towards the possibility of clinical benefit for treating ACC patients with sorafenib. Efficacy of sorafenib should be studied in a prospective-randomized clinical trial which is a challenging task due to the rarity of the disease.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"362-369"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1633490","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37355745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Orthostatic blood pressure drop and cardiovascular and psychotropic medication dosages in acutely ill geriatric inpatients. 老年急性病住院患者体位血压下降与心血管和精神药物剂量的关系。
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-10-01 Epub Date: 2019-05-29 DOI: 10.1080/17843286.2019.1623516
J Paul, F Vaillant, O Vanden Bossche, T Pepersack, S Henrard, B Boland

Objectives: . To investigate the dose-response relationship between cardiovascular or psychotropic medication dosages and falling orthostatic blood pressure in geriatric inpatients.

Methods: . This cross-sectional study included 100 consecutive geriatric inpatients of a Belgian hospital. The end points were the maximum changes of systolic (sBP) and diastolic (dBP) blood pressure in a standing up position at one or three minutes. The dosages of six classes of vascular and five classes of psychotropic medications were expressed in terms of a proportion of defined daily doses (DDD). Bivariate and multivariate linear regression models were used.

Results: . The 100 geriatric patients (85 ± 5 years, 58 % women) received 7.7 ± 4 medications (mean DDD: vascular = 1.0, psychotropic = 0.74) on the day of an orthostatic test (lying sBP: 136 ± 21; dBP: 72 ± 14 mm Hg). In a standing position, sBP and dBP fell by 12 ± 17 and 11 ± 5 mmHg, respectively. At the individual level, BP change was not correlated with vascular DDD (sBP: p = 0.07, r2 = 0.04; dBP: p = 0.59; r2 = 0.004) nor with psychotropic DDD (sBP: p = 0.14, r2 = 0.02; dBP: p = 0.82; r2 = 0.0). In multivariate analysis, sBP drop was positively associated with age, diabetes, falls history, and number of medications, but not with the DDD of any of the medication classes, while dBP drop was positively associated with age, diabetes, stroke and anaemia, but again with the DDD of any of the medication classes.

Conclusion: . No correlation was found between vascular and psychotropic medication dosages and the orthostatic blood pressure drop expressed as a continuous variable.

目的:。探讨老年住院患者心血管或精神药物剂量与体位血压下降的剂量-反应关系。方法:。本横断面研究包括100名连续在比利时一家医院住院的老年患者。终点是站立位1分钟或3分钟时收缩压(sBP)和舒张压(dBP)的最大变化。六类血管药物和五类精神药物的剂量以限定日剂量(DDD)的比例表示。采用双变量和多变量线性回归模型。结果:。100例老年患者(85±5岁,58%为女性)在直立试验当天接受了7.7±4种药物治疗(平均DDD:血管= 1.0,精神药物= 0.74)(卧位收缩压:136±21;dBP: 72±14mmhg)。站立时收缩压和舒张压分别下降12±17和11±5 mmHg。在个体水平上,血压变化与血管DDD无相关性(sBP: p = 0.07, r2 = 0.04;dBP: p = 0.59;r2 = 0.004)与精神类DDD无关(sBP: p = 0.14, r2 = 0.02;dBP: p = 0.82;r2 = 0.0)。在多变量分析中,收缩压下降与年龄、糖尿病、跌倒史和药物数量呈正相关,但与任何药物类别的DDD无关,而舒张压下降与年龄、糖尿病、中风和贫血呈正相关,但与任何药物类别的DDD呈正相关。结论:。血管和精神药物剂量与体位血压降之间没有相关性,体位血压降表现为连续变量。
{"title":"Orthostatic blood pressure drop and cardiovascular and psychotropic medication dosages in acutely ill geriatric inpatients.","authors":"J Paul,&nbsp;F Vaillant,&nbsp;O Vanden Bossche,&nbsp;T Pepersack,&nbsp;S Henrard,&nbsp;B Boland","doi":"10.1080/17843286.2019.1623516","DOIUrl":"https://doi.org/10.1080/17843286.2019.1623516","url":null,"abstract":"<p><strong>Objectives: </strong>. To investigate the dose-response relationship between cardiovascular or psychotropic medication dosages and falling orthostatic blood pressure in geriatric inpatients.</p><p><strong>Methods: </strong>. This cross-sectional study included 100 consecutive geriatric inpatients of a Belgian hospital. The end points were the maximum changes of systolic (sBP) and diastolic (dBP) blood pressure in a standing up position at one or three minutes. The dosages of six classes of vascular and five classes of psychotropic medications were expressed in terms of a proportion of defined daily doses (DDD). Bivariate and multivariate linear regression models were used.</p><p><strong>Results: </strong>. The 100 geriatric patients (85 ± 5 years, 58 % women) received 7.7 ± 4 medications (mean DDD: vascular = 1.0, psychotropic = 0.74) on the day of an orthostatic test (lying sBP: 136 ± 21; dBP: 72 ± 14 mm Hg). In a standing position, sBP and dBP fell by 12 ± 17 and 11 ± 5 mmHg, respectively. At the individual level, BP change was not correlated with vascular DDD (sBP: p = 0.07, r<sup>2</sup> = 0.04; dBP: p = 0.59; r<sup>2</sup> = 0.004) nor with psychotropic DDD (sBP: p = 0.14, r<sup>2</sup> = 0.02; dBP: p = 0.82; r<sup>2</sup> = 0.0). In multivariate analysis, sBP drop was positively associated with age, diabetes, falls history, and number of medications, but not with the DDD of any of the medication classes, while dBP drop was positively associated with age, diabetes, stroke and anaemia, but again with the DDD of any of the medication classes.</p><p><strong>Conclusion: </strong>. No correlation was found between vascular and psychotropic medication dosages and the orthostatic blood pressure drop expressed as a continuous variable.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"313-320"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1623516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37288674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Dissatisfaction and Burnout among Flemish emergency physicians: a qualitative study. 佛兰德急诊科医师的不满与倦怠:一项质性研究。
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-10-01 Epub Date: 2019-06-11 DOI: 10.1080/17843286.2019.1629077
Ine Van Bogaert, Catheline Depuydt, Said Hachimi-Idrissi

Objectives: Emergency physicians have shown difficulties to combine their private and professional life. In addition to a very stressful environment, they have to deal with multiple sources of uncertainty. These factors may lead to psychological distress. The aim of this study is to determine the factors leading to dissatisfaction and burnout among Flemish emergency physicians (EPs). Which are the barriers hindering EPs to seek help and what are the potential solutions for this problem? Methods:This is a prospective, explorative qualitative study where seven Flemish EPs were interviewed. These were in-depth semi-structured interviews. The information from the interviews was analyzed using NVivo 12. Results:The common contributors were the working schedule, the increasing number of patients, the mental and physical impact of the job and the relatively low income. The most important barrier to seek help is the existence of an unforgiving medical culture. The solutions provided by the EPs are less patients and a better financing. Conclusion:Dissatisfaction and burnout are common among the EP profession. There is a need for awareness and a change in the unforgiving medical culture to a 'no shame no blame culture'. Improvement of EPs' work schedule and income to the level of other medical specialties are other important needs. Finally, reducing the number of patient contact at the emergency department, by highlighting the difference between medical urgency rather than personal convenience.

目的:急诊医生很难将他们的私人生活和职业生活结合起来。除了压力很大的环境外,他们还必须处理各种不确定因素。这些因素可能导致心理困扰。本研究的目的是确定导致佛兰德急诊医生(EPs)的不满和倦怠的因素。有哪些障碍阻碍易犯案人士寻求帮助?这个问题有什么可能的解决办法?方法:这是一个前瞻性的,探索性质的研究,其中七个佛兰德EPs采访。这些都是深入的半结构化采访。使用NVivo 12对访谈信息进行分析。结果:常见的影响因素为工作时间安排、就诊人数增加、工作对身心的影响以及收入相对较低。寻求帮助的最重要障碍是存在一种无情的医疗文化。EPs提供的解决方案是减少患者和更好的融资。结论:不满意和职业倦怠在EP职业中普遍存在。有必要提高认识,并将无情的医疗文化转变为“不羞耻,不责备”的文化。另外一个重要的需求是,将普通医生的工作时间表和收入提高到其他医学专业的水平。最后,通过强调医疗急迫性而不是个人便利性之间的区别,减少患者在急诊科的接触次数。
{"title":"Dissatisfaction and Burnout among Flemish emergency physicians: a qualitative study.","authors":"Ine Van Bogaert,&nbsp;Catheline Depuydt,&nbsp;Said Hachimi-Idrissi","doi":"10.1080/17843286.2019.1629077","DOIUrl":"https://doi.org/10.1080/17843286.2019.1629077","url":null,"abstract":"<p><strong>Objectives: </strong>Emergency physicians have shown difficulties to combine their private and professional life. In addition to a very stressful environment, they have to deal with multiple sources of uncertainty. These factors may lead to psychological distress. The aim of this study is to determine the factors leading to dissatisfaction and burnout among Flemish emergency physicians (EPs). Which are the barriers hindering EPs to seek help and what are the potential solutions for this problem? <b>Methods:</b>This is a prospective, explorative qualitative study where seven Flemish EPs were interviewed. These were in-depth semi-structured interviews. The information from the interviews was analyzed using NVivo 12. <b>Results:</b>The common contributors were the working schedule, the increasing number of patients, the mental and physical impact of the job and the relatively low income. The most important barrier to seek help is the existence of an unforgiving medical culture. The solutions provided by the EPs are less patients and a better financing. <b>Conclusion:</b>Dissatisfaction and burnout are common among the EP profession. There is a need for awareness and a change in the unforgiving medical culture to a 'no shame no blame culture'. Improvement of EPs' work schedule and income to the level of other medical specialties are other important needs. Finally, reducing the number of patient contact at the emergency department, by highlighting the difference between medical urgency rather than personal convenience.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"329-333"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1629077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37319948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab. 康姆斯阳性难治性获得性血栓性血小板减少性紫癜在慢性髓单细胞白血病患者成功治疗利妥昔单抗。
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-10-01 Epub Date: 2019-04-22 DOI: 10.1080/17843286.2019.1608395
Ivan Krecak, Marijana Grgic Medic, Velka Gveric-Krecak, Pavle Roncevic, Sandra Bašić Kinda, Jaksa Babel, Radovan Radonic

Objectives: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare autoimmune disorder characterized by auto-antibodies to Willebrand factor (vWF) cleaving enzyme (ADAMTS13), resulting in unusually large vWF multimers that lead to platelet aggregation, microthrombi formation and microangiopathic hemolytic anemia. Hemolysis in aTTP is mechanical; thus, direct antiglobulin test (Coombs test) is usually negative. Multiple autoimmune conditions and various auto-antibodies have been described in the context of chronic myelomonocytic leukemia (CMML). In this paper, we describe the first case of CMML with auto-antibodies to ADAMTS13, presenting initially as plasmapheresis-refractory Coombs-positive aTTP. Results: Although our patient was not treated for CMML, a complete remission of aTTP was eventually achieved with rituximab. Conclusion; We propose that aTTP should be in the differential diagnosis of CMML patients with thrombocytopenia and anemia (Coombs positive or not) who develop signs of thrombotic microangiopathy. Further studies are much needed to decipher the immune-mediated processes in CMML.

目的:获得性血栓性血小板减少性紫癜(aTTP)是一种罕见的自身免疫性疾病,其特征是对Willebrand因子(vWF)切割酶(ADAMTS13)的自身抗体,导致异常大的vWF多聚体,导致血小板聚集、微血栓形成和微血管病溶血性贫血。aTTP的溶血是机械性的;因此,直接抗球蛋白试验(库姆试验)通常为阴性。在慢性髓细胞白血病(CMML)的背景下,多种自身免疫性疾病和各种自身抗体已被描述。在本文中,我们描述了第一例具有ADAMTS13自身抗体的CMML,最初表现为血浆分离难固性coombs阳性aTTP。结果:虽然我们的患者没有接受CMML治疗,但使用利妥昔单抗最终实现了aTTP的完全缓解。结论;我们建议,aTTP应作为CMML合并血小板减少和贫血(Coombs阳性或阴性)的鉴别诊断,这些患者有血栓性微血管病变的迹象。需要进一步的研究来破译CMML中免疫介导的过程。
{"title":"Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab.","authors":"Ivan Krecak,&nbsp;Marijana Grgic Medic,&nbsp;Velka Gveric-Krecak,&nbsp;Pavle Roncevic,&nbsp;Sandra Bašić Kinda,&nbsp;Jaksa Babel,&nbsp;Radovan Radonic","doi":"10.1080/17843286.2019.1608395","DOIUrl":"https://doi.org/10.1080/17843286.2019.1608395","url":null,"abstract":"<p><strong>Objectives: </strong>Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare autoimmune disorder characterized by auto-antibodies to Willebrand factor (vWF) cleaving enzyme (ADAMTS13), resulting in unusually large vWF multimers that lead to platelet aggregation, microthrombi formation and microangiopathic hemolytic anemia. Hemolysis in aTTP is mechanical; thus, direct antiglobulin test (Coombs test) is usually negative. Multiple autoimmune conditions and various auto-antibodies have been described in the context of chronic myelomonocytic leukemia (CMML). In this paper, we describe the first case of CMML with auto-antibodies to ADAMTS13, presenting initially as plasmapheresis-refractory Coombs-positive aTTP. <b>Results:</b> Although our patient was not treated for CMML, a complete remission of aTTP was eventually achieved with rituximab. Conclusion; We propose that aTTP should be in the differential diagnosis of CMML patients with thrombocytopenia and anemia (Coombs positive or not) who develop signs of thrombotic microangiopathy. Further studies are much needed to decipher the immune-mediated processes in CMML.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"357-361"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1608395","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37173030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The 2019 Flemish consensus on screening for overt diabetes in early pregnancy and screening for gestational diabetes mellitus. 2019年关于妊娠早期明显糖尿病筛查和妊娠期糖尿病筛查的佛兰德共识
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-10-01 Epub Date: 2019-07-01 DOI: 10.1080/17843286.2019.1637389
Katrien Benhalima, Caro Minschart, Paul Van Crombrugge, Peggy Calewaert, Johan Verhaeghe, Siska Vandamme, Katrien Theetaert, Roland Devlieger, Leen Pierssens, Hannah Ryckeghem, Els Dufraimont, Chris Vercammen, Ann Debie, Christophe De Block, Griet Vandenberghe, Sylva Van Imschoot, Sabine Verstraete, Luk Buyse, Johan Wens, Joke Muyldermans, Anissa Meskal, Sandy De Spiegeleer, Chantal Mathieu

Screening for gestational diabetes mellitus (GDM) is important to improve pregnancy outcomes and to prevent type 2 diabetes after pregnancy. The 'International Association of Diabetes and Pregnancy Study Groups' (IADPSG) recommends a universal one-step approach with the 75 g oral glucose tolerance test (OGTT) for screening of GDM. The IADPSG recommendation remains controversial due to the important increase in GDM prevalence and increased workload. After review of the latest evidence and based on data from the 'Belgian Diabetes in Pregnancy' study, members of the Diabetes Liga, the Flemish associations of general physicians (Domus Medica), obstetricians (VVOG), midwives (VVOB), diabetes nurse educators (BVVDV) and clinical chemists (RBSLM) have reached a new consensus on screening for GDM in Flanders. This new consensus recommends universal screening for overt diabetes when planning pregnancy or at the latest at first prenatal contact, preferably by measuring the fasting plasma glucose by using the same diagnostic criteria as in the non-pregnant state. In women with impaired fasting glycaemia, but also in normoglycemic obese women and women with a previous history of GDM, lifestyle counselling is advised with screening for GDM with a 75 g OGTT at 24 weeks. In all other women, we recommend a two-step screening strategy with a 50 g glucose challenge test (GCT) at 24 weeks followed by a 75 g OGTT when the glucose level 1 hour after the GCT ≥130 mg/dl. Diagnosis of GDM is made using the IADPSG criteria for GDM. Postpartum screening for subsequent glucose abnormalities should be advocated and organized for every woman with GDM.

妊娠期糖尿病(GDM)筛查对改善妊娠结局和预防妊娠后2型糖尿病具有重要意义。“国际糖尿病和妊娠研究小组协会”(IADPSG)推荐一种通用的一步法,即75g口服葡萄糖耐量试验(OGTT)筛查GDM。由于GDM患病率的显著增加和工作量的增加,IADPSG的建议仍然存在争议。在回顾了最新的证据和基于“比利时妊娠糖尿病”研究的数据后,糖尿病联盟的成员、佛兰德全科医生协会(Domus Medica)、产科医生协会(VVOG)、助产士协会(VVOB)、糖尿病护士教育者协会(BVVDV)和临床化学家协会(RBSLM)就佛兰德的GDM筛查达成了新的共识。这一新的共识建议在计划怀孕时或最迟在产前第一次接触时对显性糖尿病进行普遍筛查,最好是通过使用与未怀孕状态相同的诊断标准测量空腹血糖。对于空腹血糖受损的女性,以及血糖正常的肥胖女性和既往有GDM病史的女性,建议进行生活方式咨询,并在24周时进行75 g OGTT筛查GDM。对于所有其他女性,我们建议采用两步筛查策略,在24周时进行50g葡萄糖激发试验(GCT),然后在GCT后1小时血糖水平≥130mg /dl时进行75g OGTT。GDM的诊断是使用GDM的IADPSG标准进行的。产后筛查后续血糖异常应提倡和组织每一个妇女的GDM。
{"title":"The 2019 Flemish consensus on screening for overt diabetes in early pregnancy and screening for gestational diabetes mellitus.","authors":"Katrien Benhalima,&nbsp;Caro Minschart,&nbsp;Paul Van Crombrugge,&nbsp;Peggy Calewaert,&nbsp;Johan Verhaeghe,&nbsp;Siska Vandamme,&nbsp;Katrien Theetaert,&nbsp;Roland Devlieger,&nbsp;Leen Pierssens,&nbsp;Hannah Ryckeghem,&nbsp;Els Dufraimont,&nbsp;Chris Vercammen,&nbsp;Ann Debie,&nbsp;Christophe De Block,&nbsp;Griet Vandenberghe,&nbsp;Sylva Van Imschoot,&nbsp;Sabine Verstraete,&nbsp;Luk Buyse,&nbsp;Johan Wens,&nbsp;Joke Muyldermans,&nbsp;Anissa Meskal,&nbsp;Sandy De Spiegeleer,&nbsp;Chantal Mathieu","doi":"10.1080/17843286.2019.1637389","DOIUrl":"https://doi.org/10.1080/17843286.2019.1637389","url":null,"abstract":"<p><p>Screening for gestational diabetes mellitus (GDM) is important to improve pregnancy outcomes and to prevent type 2 diabetes after pregnancy. The 'International Association of Diabetes and Pregnancy Study Groups' (IADPSG) recommends a universal one-step approach with the 75 g oral glucose tolerance test (OGTT) for screening of GDM. The IADPSG recommendation remains controversial due to the important increase in GDM prevalence and increased workload. After review of the latest evidence and based on data from the 'Belgian Diabetes in Pregnancy' study, members of the Diabetes Liga, the Flemish associations of general physicians (Domus Medica), obstetricians (VVOG), midwives (VVOB), diabetes nurse educators (BVVDV) and clinical chemists (RBSLM) have reached a new consensus on screening for GDM in Flanders. This new consensus recommends universal screening for overt diabetes when planning pregnancy or at the latest at first prenatal contact, preferably by measuring the fasting plasma glucose by using the same diagnostic criteria as in the non-pregnant state. In women with impaired fasting glycaemia, but also in normoglycemic obese women and women with a previous history of GDM, lifestyle counselling is advised with screening for GDM with a 75 g OGTT at 24 weeks. In all other women, we recommend a two-step screening strategy with a 50 g glucose challenge test (GCT) at 24 weeks followed by a 75 g OGTT when the glucose level 1 hour after the GCT ≥130 mg/dl. Diagnosis of GDM is made using the IADPSG criteria for GDM. Postpartum screening for subsequent glucose abnormalities should be advocated and organized for every woman with GDM.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"340-347"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1637389","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37382410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
The OptiLUTS trial: improving care for therapy-resistant symptoms of the pelvis in Belgium. OptiLUTS试验:改善比利时骨盆治疗抵抗症状的护理
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-10-01 Epub Date: 2019-06-18 DOI: 10.1080/17843286.2019.1630109
Lynn Ghijselings, Dirk Van De Putte, François Hervé, An-Sofie Goessaert, Dimitri Beeckman, Piet Pattyn, Karel Everaert

Introduction/background: The management of therapy-resistant lower urinary tract symptoms (LUTS) and symptoms resulting from pelvic organ dysfunctions are subject to a high variability in the Belgian health-care centres. Practical guidelines and standardized patient clinical care pathways are often lacking and unadapted to the Belgian healthcare system.

Objectives: The OptiLUTS trial aims to improve the multidisciplinary care of therapy-resistant symptoms of the pelvis in the Belgian healthcare setting. Project A aims for the improvement of knowledge of 2nd line treatments for LUTS among general practitioners. In project B a treatment algorithm for the overactive bladder syndrome and non-obstructive urinary retention will be developed specifically for Belgium. In Project C a patient customized sacral neuromodulation (SNM) care pathway will be set up.

Methods: Part A: Explorative study among general practitioners by distribution of a  questionnaire. Part B: Review of existing guidelines and use of the Delphi method to obtain expert consensus. Part C: A single center comparative study to compare outcomes before and after implementation of the SNM care pathway. Patients scheduled for the first stage of Interstim therapy™ will be included (N=100). Primary endpoints are the sensitivity and specificity of a new pelvic symptom assessment tool, the conversion to implant and explantation rates.

Conclusion: There is a margin for improvement in the care process of patients with therapy-resistant symptoms of the pelvis in the Belgium healthcare system. In the OptiLUTs trial adapted guidelines and a clinical care pathway will be developed to standardize and increase the efficiency of care.

Trial registration: Approval for the trial by the Ethics Committee of the Ghent University hospital: EC/2018/0244.

介绍/背景:治疗抵抗性下尿路症状(LUTS)和盆腔器官功能障碍引起的症状的管理在比利时保健中心存在很大差异。实用的指导方针和标准化的病人临床护理途径往往缺乏和不适应比利时的医疗保健系统。目的:OptiLUTS试验旨在改善比利时医疗保健机构对骨盆治疗耐药症状的多学科护理。项目A旨在提高全科医生对LUTS二线治疗的认识。在B项目中,将专门为比利时开发一种针对膀胱过度活动综合征和非阻塞性尿潴留的治疗算法。在C项目中,将建立患者定制的骶骨神经调节(SNM)护理路径。方法:第一部分:通过发放问卷对全科医生进行探索性研究。B部分:审查现有的指导方针和德尔菲法的使用,以获得专家共识。C部分:单中心比较研究,比较SNM护理路径实施前后的结果。计划接受Interstim疗法第一阶段的患者将被纳入(N=100)。主要终点是一种新的盆腔症状评估工具的敏感性和特异性,转化为种植体和外植体的比率。结论:比利时医疗系统对骨盆耐药症状患者的护理过程仍有改进余地。在OptiLUTs试验中,将制定适应的指南和临床护理途径,以标准化和提高护理效率。试验注册:根特大学医院伦理委员会批准试验:EC/2018/0244。
{"title":"The OptiLUTS trial: improving care for therapy-resistant symptoms of the pelvis in Belgium.","authors":"Lynn Ghijselings,&nbsp;Dirk Van De Putte,&nbsp;François Hervé,&nbsp;An-Sofie Goessaert,&nbsp;Dimitri Beeckman,&nbsp;Piet Pattyn,&nbsp;Karel Everaert","doi":"10.1080/17843286.2019.1630109","DOIUrl":"https://doi.org/10.1080/17843286.2019.1630109","url":null,"abstract":"<p><strong>Introduction/background: </strong>The management of therapy-resistant lower urinary tract symptoms (LUTS) and symptoms resulting from pelvic organ dysfunctions are subject to a high variability in the Belgian health-care centres. Practical guidelines and standardized patient clinical care pathways are often lacking and unadapted to the Belgian healthcare system.</p><p><strong>Objectives: </strong>The OptiLUTS trial aims to improve the multidisciplinary care of therapy-resistant symptoms of the pelvis in the Belgian healthcare setting. Project A aims for the improvement of knowledge of 2nd line treatments for LUTS among general practitioners. In project B a treatment algorithm for the overactive bladder syndrome and non-obstructive urinary retention will be developed specifically for Belgium. In Project C a patient customized sacral neuromodulation (SNM) care pathway will be set up.</p><p><strong>Methods: </strong>Part A: Explorative study among general practitioners by distribution of a  questionnaire. Part B: Review of existing guidelines and use of the Delphi method to obtain expert consensus. Part C: A single center comparative study to compare outcomes before and after implementation of the SNM care pathway. Patients scheduled for the first stage of Interstim therapy™ will be included (N=100). Primary endpoints are the sensitivity and specificity of a new pelvic symptom assessment tool, the conversion to implant and explantation rates.</p><p><strong>Conclusion: </strong>There is a margin for improvement in the care process of patients with therapy-resistant symptoms of the pelvis in the Belgium healthcare system. In the OptiLUTs trial adapted guidelines and a clinical care pathway will be developed to standardize and increase the efficiency of care.</p><p><strong>Trial registration: </strong>Approval for the trial by the Ethics Committee of the Ghent University hospital: EC/2018/0244.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"334-339"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1630109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37338049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Uveitis as a window to diagnosis of sarcoidosis - case report and review of the literature. 葡萄膜炎作为结节病诊断的窗口——病例报告及文献复习。
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-08-01 Epub Date: 2019-05-05 DOI: 10.1080/17843286.2019.1613309
Sebastiaan Dhont, Mathias Leys, Edward De Sutter, Herwig Alaerts, Wouter Van Moerkercke

Sarcoidosis is a multisystem disease of unclear etiology with a variable clinical profile characterized by the presence of non-caseating granuloma in involved organs. The diagnosis is often challenging and based on clinical, radiological and anatomopathological data. Sarcoidosis can be benign and self-limiting, but some cases may follow a chronic, progressive course and result in severe morbidity. The disease has a predilection for the lungs and thoracic lymph nodes but can involve nearly any part of the body, possible more commonly in areas with contact to the external environment, such as the eyes and the skin. This paper is based on a case in which a recurrent uveitis led to the diagnosis of an underlying sarcoidosis.

结节病是一种病因不明的多系统疾病,临床表现多变,其特点是受累器官存在非干酪化肉芽肿。诊断通常是具有挑战性的,并基于临床,放射学和解剖病理学数据。结节病可以是良性和自限性的,但有些病例可能遵循慢性,进行性的过程,并导致严重的发病率。这种疾病以肺部和胸部淋巴结为主,但几乎可以累及身体的任何部位,可能更常见于与外部环境接触的部位,如眼睛和皮肤。本文是基于一个病例,其中复发性葡萄膜炎导致潜在结节病的诊断。
{"title":"Uveitis as a window to diagnosis of sarcoidosis - case report and review of the literature.","authors":"Sebastiaan Dhont,&nbsp;Mathias Leys,&nbsp;Edward De Sutter,&nbsp;Herwig Alaerts,&nbsp;Wouter Van Moerkercke","doi":"10.1080/17843286.2019.1613309","DOIUrl":"https://doi.org/10.1080/17843286.2019.1613309","url":null,"abstract":"<p><p>Sarcoidosis is a multisystem disease of unclear etiology with a variable clinical profile characterized by the presence of non-caseating granuloma in involved organs. The diagnosis is often challenging and based on clinical, radiological and anatomopathological data. Sarcoidosis can be benign and self-limiting, but some cases may follow a chronic, progressive course and result in severe morbidity. The disease has a predilection for the lungs and thoracic lymph nodes but can involve nearly any part of the body, possible more commonly in areas with contact to the external environment, such as the eyes and the skin. This paper is based on a case in which a recurrent uveitis led to the diagnosis of an underlying sarcoidosis.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 4","pages":"245-249"},"PeriodicalIF":1.6,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1613309","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37211774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hyperferritinemia, vasculitis and Mycoplasma pneumoniae. 高铁蛋白血症,血管炎和肺炎支原体。
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-08-01 Epub Date: 2019-03-28 DOI: 10.1080/17843286.2019.1599549
Dimitri Poddighe
Dear Sir, I read with great interest the case report by Matthys I et al., describing a young adult patient with acute, sudden and severe clinical manifestations that the authors were able to correl...
{"title":"Hyperferritinemia, vasculitis and <i>Mycoplasma pneumoniae</i>.","authors":"Dimitri Poddighe","doi":"10.1080/17843286.2019.1599549","DOIUrl":"https://doi.org/10.1080/17843286.2019.1599549","url":null,"abstract":"Dear Sir, I read with great interest the case report by Matthys I et al., describing a young adult patient with acute, sudden and severe clinical manifestations that the authors were able to correl...","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 4","pages":"311"},"PeriodicalIF":1.6,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1599549","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37100531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperferritinemia associated with systemic manifestations of Mycoplasma pneumoniae infection. 高铁蛋白血症与肺炎支原体感染的全身表现有关。
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-08-01 Epub Date: 2019-03-28 DOI: 10.1080/17843286.2019.1599569
Daniel Borsboom, Imke Matthys, Christophe Van Steenkiste
Dear Editor, We would like to comment on additional concerns that may rise about our manuscript ‘A plethora of manifestations following a Mycoplasma pneumoniae infection: a case report’[1]: 1. Rega...
{"title":"Hyperferritinemia associated with systemic manifestations of Mycoplasma pneumoniae infection.","authors":"Daniel Borsboom,&nbsp;Imke Matthys,&nbsp;Christophe Van Steenkiste","doi":"10.1080/17843286.2019.1599569","DOIUrl":"https://doi.org/10.1080/17843286.2019.1599569","url":null,"abstract":"Dear Editor, We would like to comment on additional concerns that may rise about our manuscript ‘A plethora of manifestations following a Mycoplasma pneumoniae infection: a case report’[1]: 1. Rega...","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 4","pages":"312"},"PeriodicalIF":1.6,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1599569","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37099320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare case of hemodialysis-related portosystemic encephalopathy and review of the literature. 血液透析相关门系统脑病1例及文献复习。
IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2020-08-01 Epub Date: 2019-03-28 DOI: 10.1080/17843286.2019.1595836
Barbara Geerinckx, Rachel Hellemans, Amaryllis H Van Craenenbroeck, Sven Francque, Liesbeth De Waele, Jeroen Kerstens, Pieter-Jan Van Gaal, Bart Bracke, Peter Michielsen, Thomas Vanwolleghem

Hemodialysis-related portosystemic encephalopathy (HRPSE) is a clinical phenomenon where portosystemic encephalopathy (PSE) develops without liver dysfunction, usually caused by changes in the portosystemic blood flow related to hemodialysis. We describe the case of a 22-year old patient with a transjugular intrahepatic portosystemic shunt (TIPS) who developed HRPSE several months after initiation of hemodialysis. Despite initial therapy with laxatives and neomycin symptoms recurred. It was only after relocation of the hemodialysis catheter from the superior caval vein to the femoral vein that symptoms completely resolved.

血液透析相关性门系统脑病(HRPSE)是一种无肝功能障碍的门系统脑病(PSE)的临床现象,通常由血液透析相关的门系统血流改变引起。我们描述了一例22岁的经颈静脉肝内门静脉分流(TIPS)患者,他在开始血液透析几个月后发展为HRPSE。尽管最初使用泻药和新霉素治疗,症状仍复发。只有将血液透析导管从上腔静脉移至股静脉后,症状才完全消失。
{"title":"A rare case of hemodialysis-related portosystemic encephalopathy and review of the literature.","authors":"Barbara Geerinckx,&nbsp;Rachel Hellemans,&nbsp;Amaryllis H Van Craenenbroeck,&nbsp;Sven Francque,&nbsp;Liesbeth De Waele,&nbsp;Jeroen Kerstens,&nbsp;Pieter-Jan Van Gaal,&nbsp;Bart Bracke,&nbsp;Peter Michielsen,&nbsp;Thomas Vanwolleghem","doi":"10.1080/17843286.2019.1595836","DOIUrl":"https://doi.org/10.1080/17843286.2019.1595836","url":null,"abstract":"<p><p>Hemodialysis-related portosystemic encephalopathy (HRPSE) is a clinical phenomenon where portosystemic encephalopathy (PSE) develops without liver dysfunction, usually caused by changes in the portosystemic blood flow related to hemodialysis. We describe the case of a 22-year old patient with a transjugular intrahepatic portosystemic shunt (TIPS) who developed HRPSE several months after initiation of hemodialysis. Despite initial therapy with laxatives and neomycin symptoms recurred. It was only after relocation of the hemodialysis catheter from the superior caval vein to the femoral vein that symptoms completely resolved.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 4","pages":"296-300"},"PeriodicalIF":1.6,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1595836","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37098188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Clinica Belgica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1